Professional background
Dr Valeria Fiaccadori trained in clinical haematology at Pavia University Hospital, in Italy, and completed the program in 2014. Her training included a period of research in the molecular genetics of diffuse large B cell lymphomas at the Columbia University Institute of Cancer Genetics.
After completing a fellowship in clinical research at EORTC headquarters in Brussels, she joined the Teenage and Young Adult Unit at UCLH as a clinical fellow in 2015.
Between 2017 and 2020 she undertook a PhD project within the CAR-T cell research group at UCL Cancer Institute.
She joined the team as a consultant haematologist for the Children and Young People’s Cancer Service in February 2021.
Research interests
Hodgkin Lymphoma, non Hodgkin Lymphoma, Bone Marrow Transplant, CAR-T cell therapy
Languages spoken
Italian (native language), French (basic)
Publications
André MP, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, Van Der Maazen R, Re A, Edeline V, Fermé C, Van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2017 Jun 1;35(16):1786-1794
Gotti M, Nicola M, Lucioni M, Fiaccadori V, Ferretti V, Sciarra R, Costanza M, Bono E, Molo S, Maffi A, Croci GA, Varettoni M, Frigeni M, Pascutto C, Arcaini L, Bonfichi M, Paulli M, Cazzola M. Independent prognostic impact of tumor-infiltrating macrophages in early-stage Hodgkin’s lymphoma. Hematol Oncol. 2017 Sep;35(3):296-302.
Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M. Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt)-results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative and German MDS Study Group (GMDSSG) Ann Hematol. 2015 Dec;94(12):2003-13.
Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, Bonfichi M, Bottelli C, Gabutti C, Bernasconi P, Varettoni M, Gotti M, Troletti D, Guerrera M, Fiaccadori V, Sciarra R, Ferretti VV, Alessandrino EP, Rossi G, Morra E. Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. Am J Hematol. 2014 Dec 10. doi: 10.1002/ajh.23919.
Arcaini L, Rossi D, Lucioni M, Nicola M, Bruscaggin A, Fiaccadori V, Riboni R, Ramponi A, Ferretti VV, Cresta S, Margiotta Casaluci G, Bonfichi M, Gotti M, Merli M, Maffi A, Arra M, Varettoni M, Rattotti S, Morello L, Guerrera ML, Sciarra R, Gaidano G, Cazzola M, Paulli M. The NOTCH pathway is recurrently mutated in diffuse large B cell lymphoma associated with hepatitis C virus infection. Haematologica. 2014 Nov 7. pii: haematol.2014.116855.
Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, Rattotti S, Fiaccadori V, Rusconi C, Targhetta C, Stelitano C, Levis A, Ambrosetti A, Rossi D, Rigacci L, D'Arco AM, Musto P, Chiappella A, Baldini L, Bonfichi M, Arcaini L. Outcome prediction of diffuse large B-cell lymphomas associated with hepatits C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014 Mar;99(3):489-96
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013 Mar 28;121(13):2522-8.
Lim Z.Y., Fiaccadori V, Gandhi S., Hayden J., Kenyon M., Ireland R., Marsh J, Ho A.Y.L., Mufti G.J., Pagliuca A. Impact of pre-transplant serum ferritin on outcomes of patients with myelodisplastic syndromes or secondary acute myeloid leukemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leukemia Research 2010; 24: 723-727
Reviews
Gotti M, Fiaccadori V, Bono E, Landini B, Varettoni M, Arcaini L, Bonfichi M. Therapy-Related Late Adverse Events in Hodgkin’s Lymphoma. Hindawi Publishing Corporation Lymphoma Volume 2013, Article ID 952698
Brusamolino E, Gotti M, Fiaccadori V. The Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia in Hodgkin Lymphoma has substantially Decreased in the ABVD Era Abolishing Mechloretamine and Procarbazine and Limiting Volumes and Doses of Radiotherapy. Mediterr J Hematol Infect Dis. 2012;4(1):e2012022. Epub 2012 Apr 6.
Gotti M, Fiaccadori V, Brusamolino E. Diffuse large B-cell lymphoma: update on therapy and prognosis. Clinical Investigation 2011; 1: 989-97.